Consensus in acute myeloid leukemia in Mexico.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute myeloid leukemia (AML) is a complex blood cancer originating from myeloid precursor cells.
• It is characterized by uncontrolled proliferation and impaired differentiation, leading to bone marrow failure.
• Genetic and epigenetic alterations are the primary drivers of AML development.

Purpose of the Study:

• To provide a concise overview of Acute Myeloid Leukemia.
• To highlight the underlying causes and diagnostic criteria for AML.
• To emphasize the factors influencing treatment decisions in AML patients.

Main Methods:

• Review of existing literature on AML pathogenesis and diagnosis.
• Analysis of key genetic and epigenetic changes implicated in AML.
• Summary of diagnostic standards, including bone marrow blast percentage and cytogenetics.

Main Results:

• AML arises from clonal expansion of abnormal hematopoietic precursors.
• Diagnosis hinges on identifying >20% myeloid blasts and specific cytogenetic abnormalities.
• Treatment strategies are individualized based on patient age, comorbidities, and risk stratification.

Conclusions:

• AML is a heterogeneous malignancy driven by molecular abnormalities.
• Accurate diagnosis and risk assessment are crucial for effective AML management.
• Personalized treatment approaches are essential for optimizing patient outcomes in AML.